Works matching IS 20457634 AND DT 2022 AND VI 11 AND IP 1


Results: 26
    1
    2
    3

    Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels.

    Published in:
    Cancer Medicine, 2022, v. 11, n. 1, p. 104, doi. 10.1002/cam4.4430
    By:
    • Hsu, Po‐Yao;
    • Cheng, Tzu‐Sheng;
    • Chuang, Shih‐Chang;
    • Chang, Wen‐Tsan;
    • Liang, Po‐Cheng;
    • Hsu, Cheng‐Ting;
    • Wei, Yu‐Ju;
    • Jang, Tyng‐Yuan;
    • Yeh, Ming‐Lun;
    • Huang, Ching‐I;
    • Lin, Yi‐Hung;
    • Wang, Chih‐Wen;
    • Hsieh, Ming‐Yen;
    • Hou, Nai‐Jen;
    • Hsieh, Meng‐Hsuan;
    • Tsai, Yi‐Shan;
    • Ko, Yu‐Min;
    • Lin, Ching‐Chih;
    • Chen, Kuan‐Yu;
    • Dai, Chia‐Yen
    Publication type:
    Article
    4
    5
    6
    7
    8
    9

    Comparison of survival, acute toxicities, and dose–volume parameters between intensity‐modulated radiotherapy with or without internal target volume delineation method and three‐dimensional conformal radiotherapy in cervical cancer patients: A retrospective and propensity score‐matched analysis

    Published in:
    Cancer Medicine, 2022, v. 11, n. 1, p. 151, doi. 10.1002/cam4.4439
    By:
    • Liang, Yu‐Qin;
    • Feng, Sen‐Quan;
    • Xie, Wen‐Jia;
    • Jiang, Qiong‐Zhi;
    • Yang, Yan‐Fen;
    • Luo, Ren;
    • Kidd, Elizabeth A.;
    • Zhai, Tian‐Tian;
    • Xie, Liang‐Xi
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17
    18

    Issue Information.

    Published in:
    Cancer Medicine, 2022, v. 11, n. 1, p. 1, doi. 10.1002/cam4.3988
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26